CURAS — Curasight A/S Share News
0.000.00%
Last trade - 00:00- DKK1.01bn
- DKK983.64m
- -DKK49.68m
Denmark's Curasight Q1 net loss widens
Brief: Curasight Q1 Pretax Profit DKK -16.704 Million
Denmark's Curasight reports bigger Q4 loss
Brief: Curasight Q4 Pretax Profit DKK -16.686 Million
Advisory: Alert incorrectly tagged to Curis Inc withdrawn
Advisory: Alert incorrectly tagged to Curis Inc withdrawn
Brief: Curasight Q3 Pretax Profit DKK -14.262 Million
Brief: Curasight Q2 Pretax Profit DKK -20.579 Million
Brief: Curasight A/S Says It Submits Clinical Trial Application For Phase 1 Trial With Utreat In Brain Cancer Patients
Brief: Curasight Resolves On Directed Issues And A Loan Facility
Brief: Curasight Announces Approval Of Clinical Trial Application For Phase 2 Trial With Utrace In Prostate Cancer Patients
Brief: Curasight Says Not To Proceed With Rights Issue; Evaluating Alternative Financing Opportunities
Brief: Curasight Q4 EPS DKK -0.32
Brief: Curasight Says Co Submits Clinical Trial Application For Phase 2 Trial With Utrace In Prostate Cancer Patients
Brief: Curasight Appoints CRO To Run Phase 2 Study With uTrace In Prostate Cancer
Brief: Curasight Q3 EPS DKK -0.33
Brief: Curasight Says Positive Results From The Phase 2 Study Of Utrace In Brain Cancer
Brief: Curasight And Curium Announce Global Partnership For Utrace In Prostate Cancer
Brief: Curasight And Curium Announce Global Partnership For Utrace In Prostate Cancer